By Adam L. Cataldo
Shares of Longevity Health Holdings rallied following a ruling that allows the company to maintain its listing on the Nasdaq stock exchange ahead of its proposed merger with 20/20 BioLabs.
The decision is dependent on meeting Nasdaq's initial listing rules once the deal is completed, Longevity said Wednesday.
The stock climbed 66% to $5.08 in postmarket trading after ending the regular session down 6.2% at $3.06. Shares fell to a 52-week low of $2.63 on May 14, and are down 96% in the past year.
Longevity and 20/20 executed a merger agreement last month in a deal that will lead to shareholders of 20/20 owning about 50.1% of the combined company. Once the merger is completed, Longevity said it plans to effect a 1-for-30 reverse stock split to address Nasdaq's listing requirements. The merger is expected to be completed on or before Sept. 2.
The Nasdaq Hearings Panel's decision was based on a review of both companies' financial statements and pro forma projections, Longevity said.
Pittsburgh-based Longevity describes itself as focused on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics and nutrition. 20/20 Biolabs develops and commercializes innovative laboratory tests for the early detection and the proactive management of chronic disease risk.
Write to Adam Cataldo at adam.cataldo@wsj.com
(END) Dow Jones Newswires
May 21, 2025 19:23 ET (23:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.